文献速递糖尿病甲状腺疾病

胰高血糖素样肽1受体激动剂与甲状腺癌风险

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.
PubMed 文献 · Diabetes Care · 2023-01-01

在法国国家医疗保险系统数据库中纳入2006至2018年间使用二线降糖药治疗的2型糖尿病患者,进行巢式病例对照分析,识别2014至2018年甲状腺癌病例。共2562例甲状腺癌患者与45184名对照匹配。使用胰高血糖素样肽1受体激动剂1至3年与所有甲状腺癌风险升高相关(校正HR 1.58,95%CI 1.27-1.95),与甲状腺髓样癌风险升高相关(校正HR 1.78,95%CI 1.04-3.05)。

要点

  • 使用胰高血糖素样肽1受体激动剂1至3年与所有甲状腺癌风险升高相关,校正HR 1.58(95%CI 1.27-1.95)。
  • 使用胰高血糖素样肽1受体激动剂1至3年与甲状腺髓样癌风险升高相关,校正HR 1.78(95%CI 1.04-3.05)。
  • 研究为基于法国国家医疗保险系统数据库的巢式病例对照分析,共2562例甲状腺癌患者与45184名对照匹配。

核心结论

  • 研究发现在使用胰高血糖素样肽1受体激动剂的患者中,所有甲状腺癌和甲状腺髓样癌风险升高,尤其是在治疗1至3年后。

研究设计与样本

  • 基于法国国家医疗保险系统(SNDS)数据库的巢式病例对照分析。
  • 纳入2006至2018年间接受二线降糖药治疗的2型糖尿病患者组成的队列。
  • 通过2014至2018年间的出院诊断和医疗操作识别所有甲状腺癌病例。
  • 暴露测量为6个月滞后时间前6年内的胰高血糖素样肽1受体激动剂使用,分为当前使用和基于限定日剂量的累积使用时长(≤1年、1至3年、>3年)。
  • 病例与最多20名对照按年龄、性别和糖尿病病程进行风险集抽样匹配。

主要发现

  • 共纳入2562例甲状腺癌病例,与45184名对照匹配。
  • 使用胰高血糖素样肽1受体激动剂1至3年与所有甲状腺癌风险升高相关(校正HR 1.58,95%CI 1.27-1.95)。
  • 使用胰高血糖素样肽1受体激动剂1至3年与甲状腺髓样癌风险升高相关(校正HR 1.78,95%CI 1.04-3.05)。

关键数值与推荐

  • 使用胰高血糖素样肽1受体激动剂1至3年与所有甲状腺癌风险升高相关,校正HR 1.58(95%CI 1.27-1.95)。
  • 使用胰高血糖素样肽1受体激动剂1至3年与甲状腺髓样癌风险升高相关,校正HR 1.78(95%CI 1.04-3.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer. RESEARCH DESIGN AND METHODS: A nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006 and 2018 were included in the cohort. All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 2014 and 2018. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index. RESULTS: A total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05). CONCLUSIONS: In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023. PMID: 36356111. doi:10.2337/dc22-1148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。